Cost of Refractory Crohn's Disease Before and After Ustekinumab Utilization.

ABSTRACT:

Background

Crohn's disease (CD) is associated with major health services utilization and costs. Between 2012 and 2015, ustekinumab was used off-label in Quebec, Canada for treatment of refractory CD.

Aims

We assessed the direct medical cost of adult CD patients in the 1-year pre- and 1-year postustekinumab initiation.

Methods

Data were obtained from the provincial administrative databases. CD patients dispensed subcutaneous ustekinumab in 2012 to 2014 were followed for 1 year from the date of initiation (index-date). Kaplan Meier plots were used to display time to ustekinumab discontinuation and factors associated with discontinuation were identified using multivariate Cox regression models. Direct medical costs and 95% confidence interval (CI) of gastrointestinal-rel

SUBMITTER: Rahme E 

PROVIDER: S-EPMC7678737 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature